Ekso Bionics Stock (NASDAQ:EKSO)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$11.65

52W Range

$2.73 - $13.50

50D Avg

$10.62

200D Avg

$6.93

Market Cap

$28.63M

Avg Vol (3M)

$78.94K

Beta

0.78

Div Yield

-

EKSO Company Profile


Ekso Bionics Holdings, Inc. is a global innovator in exoskeleton technology, specializing in the creation, production, sale, and leasing of these advanced devices across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. The company's operations are divided into two distinct segments: EksoHealth and EksoWorks. The EksoHealth division concentrates on engineering, manufacturing, and marketing exoskeletons designed for medical applications. Conversely, the EksoWorks segment develops and commercializes exoskeleton solutions intended for able-bodied individuals, empowering them to perform demanding, repetitive physical tasks for extended durations. Its product portfolio includes EksoNR, a sophisticated wearable bionic suit and rehabilitation tool. This device supports physical therapists and physicians in treating patients recovering from conditions such as acquired brain injury, stroke, and spinal cord injury. Additionally, the EksoUE is an assistive wearable device for the upper extremities, designed to lessen the gravitational load on the wearer's shoulders and arms. Ekso Bionics Holdings, Inc. also maintains a licensing agreement with Lockheed Martin Corporation. Founded in 2005, the company maintains its corporate headquarters in Richmond, California.

Show More

Industry

Medical - Instruments & Supplies

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

61

IPO Date

Jan 17, 2014

Website

EKSO Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Service$2.82M--
Subscription$967.00K--
Product$14.13M--
Product and Service, Other$359.00K--
EksoWorks-$1.08M$1.50M
EksoHealth-$11.83M$9.75M

Fiscal year ends in Dec 25 | Currency in USD

EKSO Financial Summary


Dec 25Dec 24Dec 23
Revenue$12.80M$17.93M$18.28M
Operating Income$-13.33M$-10.46M$-15.11M
Net Income$-11.70M$-11.33M$-15.20M
EBITDA$-13.33M$-9.45M$-13.20M
Basic EPS$-4.91$-0.56$-1.10
Diluted EPS$-4.91$-0.56$-1.10

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts


Q2 25Jul 28, 25 | 4:30 PM
Q1 25May 05, 25 | 4:30 PM
Q4 24Mar 03, 25 | 4:30 PM

Peer Comparison


TickerCompany
OSRHOSR Holdings, Inc.
AYTUAytu BioPharma, Inc.
ERNAErnexa Therapeutics Inc.
ALURAllurion Technologies Inc.
PRPHProPhase Labs, Inc.
AEMDAethlon Medical, Inc.
GOVXGeoVax Labs, Inc.
CODXCo-Diagnostics, Inc.
NVNOenVVeno Medical Corporation
ANLAdlai Nortye Ltd.